Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. FUJIFILM Holdings Corporation
  6. News
  7. Summary
    4901   JP3814000000

FUJIFILM HOLDINGS CORPORATION

(4901)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fujifilm seeks approval for Avigan as COVID-19 treatment in Japan

10/19/2020 | 06:51am EDT
FILE PHOTO: Tablets of Avigan (generic name : Favipiravir), a drug  approved as an anti-influenza drug in Japan and developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co. are displayed during a photo opportunity in Tokyo

TOKYO (Reuters) - Fujifilm Holdings Corp said on Friday it was seeking approval for its flu drug Avigan as a treatment for COVID-19 in Japan, a move that comes after a late-stage study showed reduced recovery time for patients with non-severe symptoms.

Shares of the company closed roughly 3% higher on the news.

The Nikkei newspaper last month cited https://asia.nikkei.com/Spotlight/Coronavirus/Japanese-approval-sought-for-Avigan-to-treat-COVID-19 ministry sources saying approval could be granted to the drug within a month of its application.

Japan has already approved Avigan, known generically as favipiravir, as an emergency flu medicine, which is the subject of at least 16 clinical trials around the world. But concerns remain, as the drug has been shown to cause birth defects in animal studies.

Japan's government has called on Fujifilm to triple national stockpiles of the drug. The company said in a statement it has been working with strategic partners to meet that goal and requests by other countries to supply the drug.

Fujifilm in July signed a deal with India's Dr Reddy's Laboratories and Dubai-based Global Response Aid to sell Avigan for COVID-19 globally, excluding in China, Japan and Russia.

The drug, known generically worldwide as favipiravir, has been approved in India and Russia to treat COVID-19.

Last month, Fujifilm said the late-stage study of 156 COVID-19 patients in Japan showed that symptoms of those treated with Avigan improved after 11.9 days, versus 14.7 days for a placebo group.

Results of the study, conducted by subsidiary Fujifilm Toyama Chemical, were found to be statistically significant.

(Reporting by Chris Gallagher and Sayantani Ghosh; Editing by Stephen Coates, Edwina Gibbs and Shinjini Ganguli)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
DR. REDDY'S LABORATORIES LIMITED -0.40% 5278.65 End-of-day quote.1.43%
FUJIFILM HOLDINGS CORPORATION 1.65% 8145 End-of-day quote.49.78%
NIKKEI 225 0.00% 28875.23 Real-time Quote.5.21%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) 0.00% 72.229 Delayed Quote.-1.25%
All news about FUJIFILM HOLDINGS CORPORATION
07:37aFUJIFILM  : Expands Integrated Inkjet Solutions Business
AQ
07:37aFUJIFILM  : releases new features for its FUJIFILM 42K Printbar System; a config..
AQ
07:37aFUJIFILM  : Enters Flexible Packaging Market with Launch of New Digital Inkjet W..
AQ
07:37aFUJIFILM  : to Launch X-BAR Powered by FUJIFILM Inkjet Technology, a Modular Ink..
AQ
06/23FUJIFILM  : Marketing Authorization Granted for Lutathera® Injection in Japan - ..
PU
06/14FUJIFILM  : North America Corporation, Graphic Systems Division Welcomes Packagi..
AQ
06/11FUJIFILM  : 'Art as an Essential Facet of Life and Community' - Fujifilm Announc..
AQ
06/09FUJIFILM  : Direct Edge Expands Capabilities, Increases Efficiencies, and Deligh..
AQ
05/31FUJIFILM  : Notice of Convocation
PU
05/27FUJIFILM  : Wako Pure Chemical launches “E484Q mutation detection kit&rdqu..
PU
More news
Financials
Sales 2021 2 179 B 19 650 M 19 650 M
Net income 2021 153 B 1 384 M 1 384 M
Net Debt 2021 170 B 1 534 M 1 534 M
P/E ratio 2021 20,8x
Yield 2021 1,21%
Capitalization 3 256 B 29 374 M 29 360 M
EV / Sales 2021 1,57x
EV / Sales 2022 1,42x
Nbr of Employees 73 906
Free-Float 73,9%
Chart FUJIFILM HOLDINGS CORPORATION
Duration : Period :
FUJIFILM Holdings Corporation Technical Analysis Chart | 4901 | JP3814000000 | MarketScreener
Technical analysis trends FUJIFILM HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 8 145,00 JPY
Average target price 8 135,71 JPY
Spread / Average Target -0,11%
EPS Revisions
Managers and Directors
NameTitle
Shigetaka Komori Chairman & Group Chief Executive Officer
Kenji Sukeno President, Group COO & Representative Director
Takashi Iwasaki Director & Chief Technology Officer
Kunitaro Kitamura Independent Outside Director
Tatsuo Kawada Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
FUJIFILM HOLDINGS CORPORATION49.78%28 901
ABBOTT LABORATORIES1.23%196 943
MEDTRONIC PLC7.13%168 834
BECTON, DICKINSON AND COMPANY-4.00%69 860
HOYA CORPORATION5.01%49 528
ALIGN TECHNOLOGY, INC.13.37%47 943